Investigation of Platelet Function and Aspirin Resistance in Chronic Dialysis Patient
This trial is active, not recruiting.
|Condition||end stage renal disease|
|Sponsor||National Taiwan University Hospital|
|Start date||December 2009|
|End date||June 2010|
|Trial size||300 participants|
|Trial identifier||NCT01045785, 200912018R|
The purpose of this study is to determine whether aspirin resistance has impact on cardiovascular event in dialysis patient.
PFA Col/EPI normal
PFA Col/epi showed resistance
cardiovascular event, bleeding event,and thrombosis
time frame: 1 year
Male or female participants at least 20 years old.
Inclusion Criteria: - dialysis >3 months - Hb>10 g/dl & Plt > 10000 Exclusion Criteria: - using medication which interfere PFA except aspirin - terminal disease such as malignancy - active vasculitis
|Official title||Investigation of Platelet Function and Aspirin Resistance in Chronic Dialysis Patient|
|Principal investigator||Jenqwen Huang, MD|
|Description||Dialysis patient inevitably suffered from uremic bleeding although improvement of dialysis care in the past decades. Physicians used to check bleeding time as a surrogate marker for uremic bleeding. However, bleeding time isn't accurate and as well known, is poorly correlated with clinical bleeding such as surgical bleeding. Platelet function assay (PFA) is a newly developed method to measure platelet aggregation in vitro and is validated in many sorts of platelet disorders. Recently, PFA was also used to evaluate aspirin responsiveness in patients who had taken aspirin. Our study is aim to investigate uremic thrombocytopathy via PFA of dialysis patient in Taiwan. Furthermore, we will study aspirin resistance in dialysis patient.|
Call for more information